Overview

SAFETY AND POTENTIAL EFFECT OF INNOVATIVE CELL-BASED THERAPY USING ADIPOSE-DERIVED STROMAL VASCULAR FRACTION IN PATIENTS WITH AUTOIMMUNE XEROSTOMIA

Status:
Not yet recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the tolerance and safety of autologous adipose-derived stromal vascular fraction injected in accessory salivary glands for treatment of autoimmune xerostomia in terms of adverse reactions through day 14 (D14).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Assistance Publique Hopitaux De Marseille